Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy.
Curr Eye Res 35(12):1057-62 (2010) PMID 20929291
At least one-year follow-up of a case series of young Stevens-Johnson syndrome (SJS) patients with cicatrizing ocular surface disease and recurrent inflammation (SJS-RI) treated with systemic humanized monoclonal antibody (daclizumab).
DOI: 10.3109/02713683.2010.511392
Version: za2963e q8za1 q8zb7 q8zc7 q8zdf q8ze0 q8zf1 q8zgd